The FDA approved Victoza, a Type 2 diabetes drug from Novo Nordisk, with an order that the Danish firm conduct additional safety studies of the product. The studies would focus on a possible association between Victoza, or liraglutide, and a heightened risk of medullary thyroid cancer and other related diseases.

Related Summaries